Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug

Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug

Submitted by CP Staff on June 28, 2018 - 10:10am
Source: 
CP Wire
News Tags: 
Argenx
AbbVie
ARGX-115
cancer
Headline: 
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
snippet: 

Argenx (Euronext & Nasdaq: ARGX) announced on 6/28/2018 the achievement of the second of two preclinical milestones towards an investigational new drug (IND) filing for ARGX-115, triggering a further $ 10 million payment from AbbVie.

Do Not Allow Advertisers to Use My Personal information